(Q28214125)

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Neurofibrillary tangle predominant form of senile dementia of Alzheimer type: a rare subtype in very old subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Biological markers for the diagnosis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The female sex hormone oestrogen as a neuroprotectant

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Expression analysis of BACE2 in brain and peripheral tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Apolipoprotein E allele epsilon 4 is linked to increased deposition of the amyloid beta-peptide (A-beta) in cases with or without Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

[Tau protein. A potential biological indicator for early detection of Alzheimer disease]

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Release of excess amyloid beta protein from a mutant amyloid beta protein precursor.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The sulfate moieties of glycosaminoglycans are critical for the enhancement of beta-amyloid protein fibril formation

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The Alzheimer's plaques, tangles and memory deficits may have a common origin. Part IV: can calpain act as alpha-secretase?

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Ca2+ signaling down-regulation in ageing and Alzheimer's disease: why is Ca2+ so difficult to measure?

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The role of neuronal growth factors in neurodegenerative disorders of the human brain

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

General and dramatic glial reaction in Alzheimer brains

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Choline levels are increased in cerebrospinal fluid of Alzheimer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Role of endogenous nitric oxide and peroxynitrite formation in the survival and death of motor neurons in culture.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Nitric oxide-dependent production of cGMP supports the survival of rat embryonic motor neurons cultured with brain-derived neurotrophic factor.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The cholinergic hypothesis of Alzheimer's disease: a review of progress

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

?1-Antichymotrypsin Binding to Alzheimer A? Peptides Is Sequence Specific and Induces Fibril Disaggregation In Vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Acetylcholine in human CSF: methodological considerations and levels in dementia of Alzheimer type

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Age-dependent change in the levels of Abeta40 and Abeta42 in cerebrospinal fluid from control subjects, and a decrease in the ratio of Abeta42 to Abeta40 level in cerebrospinal fluid from Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid opens a window on Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cholinesterases and the Pathology of Alzheimer Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Tetrahydrobiopterin-Free Neuronal Nitric Oxide Synthase: Evidence for Two Identical Highly Anticooperative Pteridine Binding Sites†

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Neuropeptides and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Increased tau in the cerebrospinal fluid of patients with frontotemporal dementia and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cellular and molecular basis of beta-amyloid precursor protein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Biomarkers of Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Detection of glutamine synthetase in the cerebrospinal fluid of Alzheimer diseased patients: a potential diagnostic biochemical marker

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Characterization of Alzheimer's beta -secretase protein BACE. A pepsin family member with unusual properties

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Nitric oxide, mitochondria and neurological disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid nitrite plus nitrate correlates with tetrahydrobiopterin concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Biological markers of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Increased CSF levels of nerve growth factor in patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Early-onset Alzheimer's disease due to mutations of the presenilin-1 gene on chromosome 14: a 7-year follow-up of a patient with a mutation at codon 139.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Phosphorylated tau in human cerebrospinal fluid is a diagnostic marker for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid A beta42 is increased early in sporadic Alzheimer's disease and declines with disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The tau protein in human cerebrospinal fluid in Alzheimer's disease consists of proteolytically derived fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Combined assessment of tau and neuronal thread protein in Alzheimer's disease CSF

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer's disease: a study in Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Diagnostic markers for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Stimulation of human nitric oxide synthase by tetrahydrobiopterin and selective binding of the cofactor

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Biological markers of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Plasma neuropeptide Y is reduced in patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor rece

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Recent advances in the genetics of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Tau in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Oxidative alterations in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Anti-inflammatory drugs and Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Tau Protein in Cerebrospinal Fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Tau and apo E in CSF: potential aid for discriminating Alzheimer's disease from other dementias.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Reappraising neurotransmitter-based strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Increased CSF F2-isoprostane concentration in probable AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid F2-isoprostanes are elevated in Huntington's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Reduced levels of cholesterol, phospholipids, and fatty acids in cerebrospinal fluid of Alzheimer disease patients are not related to apolipoprotein E4.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid epinephrine in Alzheimer's disease and normal aging.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal beta-amyloid ((1-42)) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Mild cognitive impairment: conceptual basis and current nosological status.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Some remarks on biological markers of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Apolipoprotein E alleles as risk factors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Tau protein and apolipoprotein E in CSF diagnostics of Alzheimer's disease: impact on non Alzheimer's dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Genes and susceptible loci of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Protective action of 17beta-estradiol and tamoxifen on glutamate toxicity in glial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Strategies that support declining cholinergic neurotransmission in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Tau protein directly interacts with the amyloid beta-protein precursor: implications for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Apolipoprotein E and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Genetic risk factors in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The cerebrospinal fluid oxidized NO metabolites, nitrite and nitrate, in Alzheimer's disease and vascular dementia of Binswanger type and multiple small infarct type.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Neurodegenerative disorders: the role of peroxynitrite

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Glutamine synthetase in cerebrospinal fluid, serum, and brain: a diagnostic marker for Alzheimer disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The cause of neuronal degeneration in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

Nitric oxide synthase neurons in different areas of normal aged and Alzheimer's brains.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021

The role of A beta 42 in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0082%2801%2900030-2

7 January 2021